Int J Psychiatry Clin Pract. 2002;6(3):167-71. doi: 10.1080/136515002760276108.
Clozapine is a first-line drug for treatment-resistant schizophrenia, but studies dealing with long-term outcome are lacking, so we decided to carry out such a study.
Patients with treatment-resistant schizophrenia who were recruited in an open-label study three years ago were re-evaluated using the same parameters: BPRS, PANSS and a side-effect rating checklist.
Nineteen out of 25 patients who participated in the initial study were available for re-evaluation. Two patients had changed to conventional neuroleptic medication, and were excluded from the study. A significant reduction in psychopathology was observed in 85% of patients. An improvement in social functioning was evident, with seven patients pursuing a career independently, and another six working with their family members since being started on clozapine. All the patients were on clozapine monotherapy, and the average daily dose was 248.21 mg. No patient required hospitalization and there was no incidence of granulocytopenia.
A significant improvement in the psychopathology and social functioning of patients was observed with much lower doses of clozapine than has been reported elsewhere. The doses used for maintenance were lower than those used in the acute phase of treatment. (Int J Psych Clin Pract 2002; 6: 167-171 ).
氯氮平是治疗抵抗性精神分裂症的首选药物，但缺乏长期疗效的研究，因此我们决定进行此项研究。
三年前参加开放性研究的治疗抵抗性精神分裂症患者采用相同的参数进行重新评估：BPRS、PANSS 和副作用评定检查表。
最初研究中 25 名患者中有 19 名可进行重新评估。2 名患者改用常规神经阻滞剂治疗，被排除在研究之外。85%的患者的精神病学症状显著减轻。社会功能改善明显，7 名患者独立从事职业，另外 6 名患者自开始氯氮平治疗以来与家人一起工作。所有患者均接受氯氮平单一治疗，平均日剂量为 248.21mg。无患者需要住院治疗，也未发生粒细胞减少症。
与其他报道相比，氯氮平的剂量更低，但患者的精神病学症状和社会功能显著改善。维持治疗的剂量低于治疗急性期的剂量。（Int J Psych Clin Pract 2002; 6: 167-171）。
